Phase 2 Readout
FLGT: Phase 2 Readout: fid-007
June 30, 2026 · fid-007. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2026
- Company
- Fulgent Genetics Inc. (FLGT)
- Drug
- fid-007
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: fid-007
- Company
- Fulgent Genetics Inc. (FLGT)
- Drug
- fid-007
- Indication
- recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)